Angela Snyder

Angela Snyder

Auto-generated profile, based on publicly available information

Angela Snyder

Georgia Health Policy Center, Georgia State University, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in AJPM Focus
Verified
Journal Article
Open access
BABrandon Attell
Brandon Attell
PBPatricia M. Barrett
Patricia M. Barrett
BPBetty S. Pace
Betty S. Pace
MMMorgan L. McLemore
Morgan L. McLemore
BMBlake T. McGee
Blake T. McGee
ASAngela B. Snyder
Angela B. Snyder
Individuals living with sickle cell disease experience high levels of morbidity that result in frequent utilization of the emergency department. The objective of this study was to provide updated national estimates of emergency department utilization associated with sickle cell disease in the U.S. Data from the National Hospital Ambulatory Medical Care Survey for the years 1999–2020 were analyzed. Complex survey analysis was utilized to produce national estimates overall and by patient age groups. On average, approximately 222,612 emergency department visits occurred annually among individuals with sickle cell disease, a nearly 13% increase from prior estimates. The annual volume of emergency department visits steadily increased over time, and pain remains the most common patient-cited reason for visiting the emergency department. Patient-reported pain levels for individuals with sickle cell disease were high, with 64% of visits associated with severe pain and 21% associated with moderate pain. Public insurance sources continue to cover most visits, with Medicaid paying for 60% of visits and Medicare paying for 12% of visits. The average time spent in the emergency department increased from previous estimates by about an hour, rising to approximately 6 hours. The average wait time to see a provider was 53 minutes. Utilization of the emergency department by individuals living with sickle cell disease remains high, especially for pain. With more than half of patients with sickle cell disease reporting severe pain levels, emergency department staff should be prepared to assess and treat sickle cell disease–related pain following evidence-based guidelines and recommendations. The findings of this study can help improve care in this population.

1 July 2016 in American Journal of Preventive Medicine
Verified
Journal Article
Open access
CNCindy E. Neunert
Cindy E. Neunert
RGRobert W. Gibson
Robert W. Gibson
PLPeter A. Lane
Peter A. Lane
PVPragya Verma-Bhatnagar
Pragya Verma-Bhatnagar
VBVaughn Barry
Vaughn Barry
ASAngela Snyder
Angela Snyder
Advances in primary prophylaxis have resulted in improved outcomes for patients with sickle cell anemia (SCA; i.e., hemoglobin SS- and Sβ(0)-thalassemia). Standard prophylactic measures include a first pneumococcal polysaccharide vaccine (PPV) and transcranial Doppler ultrasound (TCD) at age 2 years. Though efficacious, evidence suggests that delivery of these interventions is suboptimal. This study reports adherence to these measures and examines concordance across various data sources, using Registry and Surveillance for Hemoglobinopathies project data. Retrospective database and SCA center chart review identified children with SCA aged 24-36 months between January 1, 2004, and December 31, 2008. PPV and TCD administration were determined through Medicaid and Children's Health Insurance Program administrative claims data, medical record review, and Georgia Registry of Immunization Transaction and Services. Analysis was conducted in 2015. A total of 125 children met inclusion criteria. Forty-five (36.0%) children had documentation of both interventions, whereas 19 (15.2%) had no documentation of either intervention. Sixty-one (48.8%) children obtained only one intervention. Of these, more were likely to have had PPV than TCD (77.0% vs 23.0%, respectively, p<0.001). Agreement between claims data and medical record review was moderate for PPV (κ=0.55) and substantial for TCD (κ=0.74). No single, reliable data source for tracking standard of care for children with SCA statewide was found. According to study data, prophylaxis measures were not universally implemented during the surveillance period. Further research is needed to adequately track changes over time, determine risk groups, and develop methods of evaluating important metrics.

28 June 2023 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
ASAshima Singh
Ashima Singh
MSMarci Sontag
Marci Sontag
MZMei Zhou
Mei Zhou
MDMahua Dasgupta
Mahua Dasgupta
Tessa Lee CrumeTessa Lee Crume
Tessa Lee Crume
JKJulie Kanter
Julie Kanter
Background: Sickle cell disease (SCD) was first recognized in 1910 and identified as a genetic condition in 1949. However, there is not a universal clinical registry that can be used currently to estimate its prevalence. The Sickle Cell Data Collection (SCDC) program, funded by the Centers for Disease Control and Prevention, funds state-level grantees to compile data within their states from various sources including administrative claims to identify individuals with SCD. The performance of the SCDC administrative claims case definition has been validated in a pediatric population with SCD, but it has not been tested in adults. Objective: The objective of our study is to evaluate the discriminatory ability of the SCDC administrative claims case definition to accurately identify adults with SCD using Medicaid insurance claims data. Methods: Our study used Medicaid claims data in combination with hospital-based medical record data from the Alabama, Georgia, and Wisconsin SCDC programs to identify individuals aged 18 years or older meeting the SCDC administrative claims case definition. In order to validate this definition, our study included only those individuals who were identified in both Medicaid’s and the partnering clinical institution’s records. We used clinical laboratory tests and diagnostic algorithms to determine the true SCD status of this subset of patients. Positive predictive values (PPV) are reported overall and by state under several scenarios. Results: There were 1219 individuals (354 from Alabama and 865 from Georgia) who were identified through a 5-year time period. The 5-year time period yielded a PPV of 88.4% (91% for data from Alabama and 87% for data from Georgia), when only using data with laboratory-confirmed (gold standard) cases as true positives. With a narrower time period (3-year period) and data from 3 states (Alabama, Georgia, and Wisconsin), a total of 1432 individuals from these states were included in our study. The overall 3-year PPV was 89.4% (92%, 93%, and 81% for data from Alabama, Georgia, and Wisconsin, respectively) when only considering laboratory-confirmed cases as true cases. Conclusions: Adults identified as having SCD from administrative claims data based on the SCDC case definition have a high probability of truly having the disease, especially if those hospitals have active SCD programs. Administrative claims are thus a valuable data source to identify adults with SCD in a state and understand their epidemiology and health care service usage.

20 March 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Open access
SPSusan T. Ma Paulukonis
Susan T. Ma Paulukonis
ASAngela Snyder
Angela Snyder
MSMatthew P. PhD Smeltzer
Matthew P. PhD Smeltzer
ASAnkit N. Mbbs Sutaria
Ankit N. Mbbs Sutaria
IHIsabel Hurden
Isabel Hurden
SRSarah L. Reeves
Sarah L. Reeves
The sickle cell mutation increases morbidity in those with sickle cell disease (SCD) and potentially sickle cell trait, impacting pulmonary, coagulation, renal, and other systems that are implicated in COVID-19 severity. There are no population-based registries for hemoglobinopathies, and they are not tracked in COVID-19 testing. We used COVID-19 test data from 2 states linked to newborn screening data to estimate COVID outcomes in people with SCD or trait compared with normal hemoglobin. We linked historical newborn screening data to COVID-19 tests, hospitalization, and mortality data and modeled the odds of hospitalization and mortality. Georgia’s cohort aged 0 to 12 years; Michigan’s, 0 to 33 years. Over 8% of those in Michigan were linked to positive COVID-19 results, and 4% in Georgia. Those with SCD showed significantly higher rates of COVID-19 hospitalization than the normal hemoglobin Black cohort, and Michigan had higher rates of mortality as well. Outcomes among those with the trait did not differ significantly from the normal hemoglobin Black group. People with SCD are at increased risk of COVID-19–related hospitalization and mortality and are encouraged to be vaccinated and avoid infection. Persons with the trait were not at higher risk of COVID-related severe outcomes.

12 June 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
MKMariam Kayle
Mariam Kayle
MZMei Zhou
Mei Zhou
BABrandon K. Attell
Brandon K. Attell
JVJhaqueline Valle
Jhaqueline Valle
SRSarah L. Reeves
Sarah L. Reeves
ASAngela B. Snyder
Angela B. Snyder
Background: Whereas pregnancy in sickle cell disease (SCD) is considered high risk, there is limited understanding of pregnancy‐ and SCD‐related morbidity to inform clinical practice and health policy.Procedure: This retrospective cohort study aimed to describe pregnancy‐ and disease‐related morbidity among individuals with SCD for up to 1 year postpartum using Medicaid claims (2010–2018) linked with newborn screening and clinical reports from four state Sickle Cell Data Collection programs. Medicaid enrollees aged 15–44 years with SCD were included. The most recent delivery hospitalization and associated complications were identified using the International Classification of Diseases nineth and tenth revisions. The main outcomes included pregnancy‐ and disease‐related complications during pregnancy, at delivery, and up to 1 year post‐delivery.Results: A total of 1286 individuals met the inclusion criteria (43% were 15–24 years old, 50% were 25–34 years old). Most (n = 957, 74%) were enrolled in Medicaid before pregnancy, 88% (n = 1132) were enrolled within their first 16 weeks of pregnancy, and 68% (n = 876) maintained Medicaid coverage for 1 year postpartum. High incidence of SCD‐related morbidities including vaso‐occlusive crisis (37.6%) and acute chest syndrome (5.8%), and obstetric complications—preeclampsia/eclampsia (9.6%), antepartum hemorrhage (24.2%), and preterm delivery (28.1%)—were reported through 60 days postpartum. Many individuals continued to have SCD‐related complications beyond the 60‐day postpartum period, including more than one‐third having a vaso‐occlusive crisis.Conclusions: Individuals with SCD are at increased risk of pregnancy‐ and SCD‐related morbidity throughout the perinatal period. Medicaid policies that ensure continuous coverage and encourage comprehensive multidisciplinary care models may reduce both SCD and obstetric complications and promote better maternal outcomes.

3 May 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
JSJiajing Scarlette Shi
Jiajing Scarlette Shi
ASAnkit Sutaria
Ankit Sutaria
SLSangeetha Lakshmanan
Sangeetha Lakshmanan
BABrandon Attell
Brandon Attell
MZMei Zhou
Mei Zhou
ASAngela Snyder
Angela Snyder
Introduction: Despite the importance of timely vaccine completion for protection from infectious disease, there is limited knowledge of the immunization adherence rates of children with sickle cell disease (SCD). Methods: This is a retrospective cohort study comparing the immunization rates of children with SCD to those with sickle cell trait between 2008 and 2019 in Georgia. Completion rates for each vaccine and the proportion of children with up‐to‐date status at 24 and 35 months were calculated and compared between the cohorts. Chi‐square tests with odds ratios (OR) for differences and 95% confidence intervals (CIs) were reported on the overall up‐to‐date rates and rates for individual vaccines at 24 and 35 months for the two cohorts. Results: Children with SCD had higher up‐to‐date rates than children with sickle cell trait at 24 and 35 months. At 35 months, the overall up‐to‐date rates (OR = 1.17; 95% CI, 1.04‐1.31; p  = .004) and the four‐dose pneumococcal conjugate vaccine series (OR = 1.36; 95% CI, 1.18‐1.57; p  < .001) were significantly different between the groups. Both cohorts had the highest completion rates for the hepatitis B series and the lowest rates for the varicella vaccine. Doses of diphtheria, tetanus, and acellular pertussis vaccine; varicella; and pneumococcal conjugate vaccines were most commonly missed by children in both cohorts. Conclusions: Children with SCD have better immunization coverage than children with sickle cell trait, but there is an opportunity for improvement. Policymakers and healthcare professionals should focus on increasing access to care coordination services among children with SCD to ensure on‐time and preventive healthcare services.